Rochester, Minnesota Clinical Trials

A listing of Rochester, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Effect of 1 25-dihydroxyvitamin D3 Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

The aim of this study is to assess the effects of 1,25(OH)2D3 on insulin secretion by the pancreas and glucose utilization by skeletal muscle as well as to determine the effects of 1,25(OH)2D3 on muscle strength in pre-diabetic persons

body mass index
prediabetic state
insulin
serum glucose
fasting
Mayo Clinic
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

Mayo Clinic
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +29 other locations
None

Mayo Clinic Rochester
 (1.8 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

dementia
aphasia
progranulin
pick's disease
Mayo Comprehensive Cancer Center - PPDS
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.

memantine
direct bilirubin
effects of radiation therapy
cancer
pediatric
Mayo Clinic
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

proteasome inhibitor
monoclonal antibodies
lenalidomide
refractory multiple myeloma
cell transplantation
Investigational Site Number 8400005
 (1.8 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +7 other locations
None

Mayo Clinic Rochester
 (1.8 away) Contact site
  • 0 views
  • 19 May, 2025
  • +12 other locations
None

Mayo Clinic Rochester
 (1.8 away) Contact site
  • 0 views
  • 19 May, 2025
  • +13 other locations
AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid

There is an epidemic of thyroid cancer that is harmful to patients and the medical system. The study hypothesizes that the use of an electronic conversation aid during clinical visits can help patients and clinicians collaborate when deciding the next step in management for a thyroid nodule. The study aims …

cancer
thyroid nodule
thyroid biopsy
aim1
Mayo Clinic
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

proteasome inhibitor
daratumumab
lenalidomide
refractory multiple myeloma
thalidomide
Mayo Clinic
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations